Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidiolex in biochemically recurrent prostate cancer
NCT04428203Phase 1Completed
- Start
- Aug 2020
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of cannabidiol in prostate cancer (PCa) (3 arms). Primary endpoint: Dose-limiting Toxicities at 90 days. Started Aug 2020; status: completed.
02
Drugs
cannabidiol
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04428203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428203.